| Mrs Noreen Ellen Borino, NP | |
|
1490 E Foremaster Dr Ste 360, St George, UT 84790-4508 | |
| (435) 359-3115 | |
| (435) 291-1096 |
| Full Name | Mrs Noreen Ellen Borino |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 1490 E Foremaster Dr Ste 360, St George, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396909826 | NPI | - | NPPES |
| 1396909826 | Medicaid | NV | |
| APRN00223 | Other | NV | STATE LICENSE |
| APRN00223 | Other | OTHER |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Noreen Ellen Borino, NP 1490 E Foremaster Dr Ste 360, St George, UT 84790-4508 Ph: (435) 359-3115 | Mrs Noreen Ellen Borino, NP 1490 E Foremaster Dr Ste 360, St George, UT 84790-4508 Ph: (435) 359-3115 |
News Archive
Heart disease is the single leading cause of death for American women. Nearly twice as many women in the United States die of heart disease, stroke and other cardiovascular diseases than from all forms of cancer, including breast cancer.
3Care Therapeutics, a manufacturer of nutritional supplements for treating common chronic health problems, announces the release of the 3Care BioSystems Program, a simplified nutritional program that helps practitioners improve patients' health and achieve thriving nutrition practices. The Program is administered via a free, easy-to-use software application; and unlike more complicated therapeutic lifestyle change programs, the 3Care Program encourages improved health outcomes through better patient compliance.
In an Addiction analysis of relevant published studies, investigators found some evidence for a positive association between anxiety during childhood and adolescence with later alcohol use disorders.
ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that on August 25, 2010, the United States District Court for the District of Columbia denied sanofi-aventis U.S. LLC's request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the Abbreviated New Drug Application (ANDA) filed by the Company's collaboration partner, Sandoz, for enoxaparin sodium injection USP, a generic version of Lovenox®. The decision is subject to appeal.
› Verified 6 days ago